JP2003518507A5 - - Google Patents

Download PDF

Info

Publication number
JP2003518507A5
JP2003518507A5 JP2001548135A JP2001548135A JP2003518507A5 JP 2003518507 A5 JP2003518507 A5 JP 2003518507A5 JP 2001548135 A JP2001548135 A JP 2001548135A JP 2001548135 A JP2001548135 A JP 2001548135A JP 2003518507 A5 JP2003518507 A5 JP 2003518507A5
Authority
JP
Japan
Prior art keywords
vector
inducer
inhibitor
description
obstruction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001548135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518507A (ja
Filing date
Publication date
Priority claimed from GBGB9930616.9A external-priority patent/GB9930616D0/en
Application filed filed Critical
Publication of JP2003518507A publication Critical patent/JP2003518507A/ja
Publication of JP2003518507A5 publication Critical patent/JP2003518507A5/ja
Pending legal-status Critical Current

Links

JP2001548135A 1999-12-24 2000-12-22 免疫系の活性化および阻害 Pending JP2003518507A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930616.9A GB9930616D0 (en) 1999-12-24 1999-12-24 Activation and inhibition of the immune system
GB9930616.9 1999-12-24
PCT/GB2000/004925 WO2001047543A2 (en) 1999-12-24 2000-12-22 Activation and inhibition of the immune system

Publications (2)

Publication Number Publication Date
JP2003518507A JP2003518507A (ja) 2003-06-10
JP2003518507A5 true JP2003518507A5 (cg-RX-API-DMAC7.html) 2008-02-28

Family

ID=10867023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548135A Pending JP2003518507A (ja) 1999-12-24 2000-12-22 免疫系の活性化および阻害

Country Status (12)

Country Link
US (2) US7915009B2 (cg-RX-API-DMAC7.html)
EP (2) EP1852123A3 (cg-RX-API-DMAC7.html)
JP (1) JP2003518507A (cg-RX-API-DMAC7.html)
CN (2) CN1254272C (cg-RX-API-DMAC7.html)
AT (1) ATE390929T1 (cg-RX-API-DMAC7.html)
AU (1) AU781496B2 (cg-RX-API-DMAC7.html)
CA (1) CA2394880A1 (cg-RX-API-DMAC7.html)
DE (1) DE60038503T2 (cg-RX-API-DMAC7.html)
ES (1) ES2302707T3 (cg-RX-API-DMAC7.html)
GB (1) GB9930616D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ519438A (cg-RX-API-DMAC7.html)
WO (1) WO2001047543A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1345617A2 (en) * 2000-12-22 2003-09-24 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
JP2003055202A (ja) * 2001-08-15 2003-02-26 Hiroyuki Hanai 炎症性腸疾患の予防・治療剤
CN1306964C (zh) * 2002-05-29 2007-03-28 安琪士摩奇株式会社 治疗和预防炎症性疾病的诱饵组合物
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor
WO2004027063A1 (en) * 2002-09-19 2004-04-01 Institut National De La Sante Et De La Recherche Medicale-Inserm Use of sirnas for gene silencing in antigen presenting cells
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
US20050147608A1 (en) * 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
KR20080052549A (ko) * 2005-06-23 2008-06-11 베이롤 칼리지 오브 메드신 네거티브 면역 조절인자의 조절 및 면역요법을 위한 적용
CA2623153A1 (en) * 2005-09-20 2007-03-29 London Health Sciences Centre Research Inc. The use of sirnas in organ storage/reperfusion solutions
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
CA2702340C (en) * 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP6313203B2 (ja) * 2011-07-18 2018-04-18 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションUniversity Of Kentucky Research Foundation Alu−rna誘導変性からの細胞の保護及び細胞保護用阻害剤
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
EP3043641B1 (en) * 2013-09-12 2019-09-11 Icahn School of Medicine at Mount Sinai Methods of making transgenic animals with t cell receptors that are specific to a flourescent protein
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US20150342961A1 (en) * 2014-06-03 2015-12-03 Hai-Hui Xue Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10420836B2 (en) 2015-10-08 2019-09-24 Emory University Methods of immunizing a subject and compositions related thereto
CR20210587A (es) 2019-05-31 2022-02-11 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
EP0500785B1 (en) 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
US5597898A (en) 1995-02-15 1997-01-28 Yale University NF-κB activation regulatory protein, IκB-β
WO1997001340A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal mast cell stabilizers
EP0779361A3 (en) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FI990180A7 (fi) * 1996-08-12 1999-03-08 Celgene Corp Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
CA2263835C (en) * 1996-08-26 2012-02-21 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US6924308B1 (en) 1997-07-30 2005-08-02 Howard L. Elford Therapeutic process for inhibiting NF-κB
US5952483A (en) 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
EP0897009A3 (en) 1997-08-04 1999-06-09 Smithkline Beecham Plc HKABY60 polypeptides
JPH1171278A (ja) * 1997-09-01 1999-03-16 Kanegafuchi Chem Ind Co Ltd 転写因子NF−κB活性化阻害剤
GB9719238D0 (en) 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US5965421A (en) 1997-11-26 1999-10-12 Human Genome Sciences, Inc. Human IRAK-2
WO1999042137A2 (en) 1998-02-19 1999-08-26 Peter Bromley Stress promoter control of therapeutic genes in gene therapy: compositions and methods
ATE309352T1 (de) * 1998-05-06 2005-11-15 Vlaams Interuniv Inst Biotech Inhibitoren der nf-kb aktivierung
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
EP1345617A2 (en) 2000-12-22 2003-09-24 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods

Similar Documents

Publication Publication Date Title
Maloy et al. Intralymphatic immunization enhances DNA vaccination
JP2010516290A5 (cg-RX-API-DMAC7.html)
CN103998056B (zh) 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
JP2018509935A5 (cg-RX-API-DMAC7.html)
JP2007528217A (ja) スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
JP2023518340A5 (cg-RX-API-DMAC7.html)
JP2019527737A (ja) Il12を発現する腫瘍溶解性ラブドウイルス
Tan et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen
Cong et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
JP5427027B2 (ja) Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
JP2009520758A5 (cg-RX-API-DMAC7.html)
JP2015529677A5 (cg-RX-API-DMAC7.html)
Birnbaum et al. Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2′, 3′ cyclic nucleotide 3′ phosphodiesterase that is cross‐reactive with a heat shock protein alters the course of EAE
CN106163540A (zh) 用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合
CN100467063C (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
JP2010535504A5 (cg-RX-API-DMAC7.html)
JP2008500043A (ja) 黄色ブドウ球菌に対する感染防御免疫応答を誘導するためのポリペプチド
JP2005512518A5 (cg-RX-API-DMAC7.html)
JP2006523185A5 (cg-RX-API-DMAC7.html)
Guo et al. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma
Rego et al. Monophosphoryl lipid-A: a promising tool for Alzheimer’s disease toll
JP2007524688A (ja) T細胞免疫応答阻害剤
WO2023280303A1 (zh) Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
WO2009132283A2 (en) Method for treating autoimmune disorders